Despite what the title suggests, there is currently no FDA-approved topical treatment specifically indicated for sebaceous hyperplasia. As of early 2026, every topical option used for these small, yellowish bumps on the skin remains off-label. That may come as a disappointment to the millions of adults — particularly those over 40 — who develop these benign but cosmetically frustrating overgrowths of sebaceous glands. For someone noticing a cluster of flesh-colored papules across their forehead or cheeks, the reality is that dermatologists are still working with a patchwork of repurposed medications and in-office procedures rather than a single, purpose-built topical solution.
That said, the treatment landscape is not standing still. Several promising developments have emerged in the past year, including clinical research into high-frequency focused ultrasound and the FDA clearance of a novel energy-based device called the CellFX System. Meanwhile, off-label topical options like retinoids and trichloroacetic acid continue to offer partial relief. This article breaks down what actually works today, what the research shows, and what may be coming next for people dealing with sebaceous hyperplasia.
Table of Contents
- Is There Really a First Approved Topical for Sebaceous Hyperplasia?
- What Off-Label Topical Treatments Do Dermatologists Actually Use?
- Oral Isotretinoin — The Most Effective Pharmaceutical Option and Its Trade-Offs
- Procedural Alternatives — Comparing Energy-Based and Destructive Techniques
- New Research — High-Frequency Focused Ultrasound and Its Limitations
- Why Sebaceous Hyperplasia Gets Overlooked by Drug Developers
- What Patients Can Expect Going Forward
- Conclusion
- Frequently Asked Questions
Is There Really a First Approved Topical for Sebaceous Hyperplasia?
No — and this is worth stating clearly because misleading headlines can send patients down the wrong path. No pharmaceutical company has received FDA approval for a topical drug with a specific indication for sebaceous hyperplasia. The condition occupies an odd space in dermatology: common enough that most dermatologists see it regularly, yet benign enough that it has not attracted the kind of large-scale clinical trial investment that conditions like acne or psoriasis receive. One drug that occasionally sparks confusion is clascoterone, marketed as WINLEVI cream 1%.
The FDA approved clascoterone for acne vulgaris in 2020, and because it works by targeting androgen receptors in sebaceous glands, some have speculated about its potential relevance to sebaceous hyperplasia. However, clascoterone carries no indication for sebaceous hyperplasia, and no published Phase 3 trial has evaluated it for this use. Using it off-label for these lesions would be a conversation between patient and dermatologist — not something backed by regulatory approval. The distinction matters because “FDA-approved for a condition” and “sometimes used off-label” are fundamentally different levels of evidence. Patients searching online for a definitive topical cure should be cautious about any product or article claiming otherwise.
What Off-Label Topical Treatments Do Dermatologists Actually Use?
The most commonly prescribed topical agents for sebaceous hyperplasia include tretinoin cream (typically in the 0.025% to 0.05% range) and salicylic acid preparations. Tretinoin, a retinoid, works by accelerating skin cell turnover and can modestly reduce the prominence of lesions over several months of consistent use. Salicylic acid helps by exfoliating the surface of the bumps. Neither eliminates lesions entirely in most patients, but both can improve appearance enough to satisfy people with mild cases. Trichloroacetic acid, or TCA, is another topical agent used in-office at higher concentrations.
A dermatologist applies it directly to individual lesions, causing controlled destruction of the overgrown gland tissue. This approach tends to be more effective than at-home retinoid creams, but it requires professional application, may need multiple sessions, and carries a risk of scarring or pigment changes — particularly in darker skin tones. It is not something to attempt at home with over-the-counter chemical peel products. However, if someone has dozens of lesions across their face, topical approaches alone may not be practical. Spot-treating thirty or forty individual bumps with TCA or waiting months for a retinoid cream to make a marginal difference can feel inadequate. This is where systemic treatment and procedural options enter the conversation — and where patients need to weigh convenience against effectiveness.
Oral Isotretinoin — The Most Effective Pharmaceutical Option and Its Trade-Offs
For patients with extensive sebaceous hyperplasia, oral isotretinoin remains the most potent pharmaceutical intervention, though it is used strictly off-label for this condition. A study of 20 patients treated with isotretinoin at a dose of 1 mg/kg/day for two months demonstrated striking results: lesion counts dropped from an average of 24 per patient down to just 2. That level of clearance far exceeds what any topical agent has achieved in published research. The catch — and it is a significant one — is that lesions frequently recur after the medication is discontinued.
Isotretinoin shrinks sebaceous glands while it is actively being taken, but once the drug leaves the system, the glands can gradually enlarge again. This puts patients in a difficult position: the drug works, but its effects are not permanent, and long-term isotretinoin use carries well-documented side effects including severe dryness, elevated liver enzymes, mood changes, and the absolute contraindication in pregnancy due to teratogenic effects. For an older adult dealing with sebaceous hyperplasia as a cosmetic concern, the risk-benefit calculation of systemic isotretinoin looks very different than it does for a teenager with severe cystic acne. Many dermatologists reserve this option for patients who have tried and failed other approaches, or whose lesion burden is particularly high and distressing.
Procedural Alternatives — Comparing Energy-Based and Destructive Techniques
Beyond topical and oral medications, several procedural treatments target sebaceous hyperplasia with varying degrees of success. Electrodessication, cryotherapy with liquid nitrogen, and laser ablation have all been used for decades. Each works by physically destroying the overgrown gland tissue. Electrodessication uses electrical current, cryotherapy uses extreme cold, and lasers use focused light energy. All can be effective for individual lesions, but they share common limitations: potential scarring, the need for repeat treatments as new lesions appear, and variable outcomes depending on skin type. A newer entrant is the CellFX System, which uses a technology called Nano-Pulse Stimulation.
The FDA cleared CellFX as a device for treating sebaceous hyperplasia in patients with Fitzpatrick skin types I through III — meaning fair to medium skin tones. This is notable because it represents the only FDA-cleared intervention specifically for sebaceous hyperplasia, though it is a device clearance, not a drug approval. Patients with darker skin are not covered by this clearance, which highlights a persistent gap in dermatologic treatment access. When comparing these procedural options, the trade-off generally comes down to precision versus convenience. Laser and CellFX treatments tend to be more targeted with potentially less collateral tissue damage, but they cost more and may not be available outside major metropolitan dermatology practices. Electrodessication and cryotherapy are more widely available and cheaper per session, but may carry higher risks of post-treatment scarring or pigmentation changes.
New Research — High-Frequency Focused Ultrasound and Its Limitations
One of the more intriguing developments in 2025 was a clinical study evaluating high-frequency focused ultrasound, or HIFU, as a non-invasive treatment for sebaceous hyperplasia. Published in the Journal of Clinical Medicine in February 2025, this research examined whether ultrasound energy could selectively target and reduce sebaceous gland overgrowth without breaking the skin surface. The study focused on efficacy, safety, and patient acceptability — three pillars that any new treatment modality needs to address. While this research is encouraging as a proof of concept, it is important to temper expectations.
A single clinical study does not constitute the level of evidence required for FDA approval or widespread clinical adoption. The study’s sample size, follow-up duration, and comparison against existing treatments all matter, and larger, controlled trials would be needed before HIFU could be recommended as a standard approach. Patients who encounter this research should view it as a promising early signal rather than a validated treatment option. There is also a practical limitation worth noting: HIFU devices are expensive, require trained operators, and are not yet widely available for this specific indication. Even if the technology proves effective in larger trials, access could remain limited to academic medical centers and specialized dermatology clinics for years before becoming mainstream.
Why Sebaceous Hyperplasia Gets Overlooked by Drug Developers
The absence of an FDA-approved topical treatment for sebaceous hyperplasia is not an accident — it reflects how pharmaceutical economics work. Developing a new drug through FDA approval costs hundreds of millions of dollars and requires large, multi-site clinical trials. Sebaceous hyperplasia, while common, is a cosmetic concern rather than a medically dangerous condition.
The gland overgrowths are benign, carry no cancer risk, and cause no physical symptoms beyond their appearance. This makes it difficult for a pharmaceutical company to justify the investment, since insurers are unlikely to cover a cosmetic treatment and the out-of-pocket market may not be large enough to recoup development costs. This is the same dynamic that leaves many common but non-dangerous skin conditions underserved. Until a company identifies a viable commercial pathway — perhaps through a combination indication that also covers acne or rosacea — a dedicated topical for sebaceous hyperplasia is likely to remain an unmet need.
What Patients Can Expect Going Forward
Looking ahead, the most realistic near-term progress for sebaceous hyperplasia treatment is likely to come from devices rather than drugs. The CellFX clearance has set a precedent, and additional energy-based technologies may follow as the evidence base grows.
Meanwhile, ongoing research into androgen receptor biology and sebaceous gland function could eventually yield topical candidates, particularly if a drug initially developed for another indication — like clascoterone — shows promise in smaller trials for sebaceous hyperplasia. For now, patients should work with a board-certified dermatologist to develop a realistic treatment plan based on the number and location of their lesions, their skin type, and their tolerance for procedures versus daily topical regimens. The honest answer is that managing sebaceous hyperplasia in 2026 requires patience, realistic expectations, and a willingness to combine approaches rather than relying on a single solution.
Conclusion
Sebaceous hyperplasia remains a condition without a single, definitive topical cure. Despite occasional headlines suggesting otherwise, no FDA-approved topical drug exists for this specific indication as of March 2026. The current toolkit includes off-label retinoids and chemical agents, systemic isotretinoin for severe cases, and a growing array of procedural options including the FDA-cleared CellFX device and emerging ultrasound-based approaches.
The most productive step for anyone dealing with these lesions is a frank conversation with a dermatologist about what realistic improvement looks like. Some patients achieve satisfactory results with a retinoid cream and occasional in-office TCA applications. Others with more extensive involvement may benefit from device-based treatments or a short course of isotretinoin with the understanding that maintenance may be needed. The field is moving forward — just not as fast as some headlines would suggest.
Frequently Asked Questions
Is sebaceous hyperplasia the same as acne?
No. While both involve sebaceous glands, acne results from clogged pores and bacterial infection, whereas sebaceous hyperplasia is a benign overgrowth of the gland itself. Treatments overlap in some cases — retinoids and isotretinoin are used for both — but the underlying conditions are different.
Can I treat sebaceous hyperplasia at home?
Over-the-counter retinol products and salicylic acid cleansers may modestly reduce the appearance of mild lesions, but they are far less effective than prescription-strength options. Attempting to extract or pop sebaceous hyperplasia bumps at home can cause scarring and infection. Professional evaluation is recommended.
Does insurance cover sebaceous hyperplasia treatment?
In most cases, no. Because sebaceous hyperplasia is classified as a cosmetic concern, insurers typically do not cover treatments. Procedural options like laser or CellFX can cost several hundred dollars per session out of pocket.
Will sebaceous hyperplasia go away on its own?
Generally, no. Sebaceous hyperplasia tends to persist and may slowly increase in number over time, particularly in people over 40 and those with oilier skin types. Without treatment, existing lesions typically remain indefinitely.
Is the CellFX System available everywhere?
No. The CellFX System is FDA-cleared only for patients with Fitzpatrick skin types I through III and is currently available at select dermatology practices. Availability is more limited outside major urban areas, and patients may need to travel to access this technology.
